Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1CNS 1

Conditions

Sarcoma 1Ovarian Neoplasms 1Neurofibromatosis 2 1Hemangiosarcoma 1Carcinoma, Ovarian Epithelial 1

Interventions

Cyclophosphamide 910Carboplatin 788pembrolizumab 747Paclitaxel 744Bevacizumab 716Cisplatin 709Gemcitabine 621Docetaxel 584Rituximab 558Radiotherapy 548Dexamethasone 511Nivolumab 491Doxorubicin 445Fluorouracil 392Capecitabine 382Etoposide 358Pemetrexed 339Cytarabine 335Oxaliplatin 335Lenalidomide 328Prednisone 327Erlotinib Hydrochloride 323fludarabine phosphate 316Trastuzumab 305Leucovorin 299fludarabine 296Vincristine 288Bortezomib 284Filgrastim 284Cetuximab 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Vascular Endothelial Growth Factor A × Clear all
NCT01551745 2021-10-19

Salvage Ovarian FANGâ„¢ Vaccine + Bevacizumab

Gradalis, Inc.

Phase 2 Completed
5 enrolled 9 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT01767792 2021-02-12

Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas

University of Alabama at Birmingham

Phase 2 Completed
22 enrolled 14 charts
CNS

Neurofibromatosis 2

NCT00288015 2018-06-25

Bevacizumab in Treating Patients With Angiosarcoma

Northwestern University

Phase 2 Completed
32 enrolled 12 charts
Sarcoma

Hemangiosarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡